Lupus & Connective Tissue Diseases
Latest News
FDA OKs First-in-Class Agent for Pulmonary Arterial Hypertension
FDA has granted breakthrough designation for Merck’s sotatercept, an activin signaling inhibitor for treatment of PAH.
Latest News
Multiple Social Disadvantages Linked to Progressively Worse JIA and Pediatric Lupus
Children living in disadvantaged areas had higher rates of active disease in JIA and lupus, studies suggest.
From the Journals
New Analysis Defines Three Distinct Sjögren Syndrome Subgroups
Those with high systemic disease activity but low symptom burden fared worse over time.
From the Journals
Safe Steroid Tapering in Lupus: Reducing Flares, Damage
Cautious tapering of glucocorticoids might be feasible even in serologically active clinically quiescent patients with systemic lupus...
News from the FDA/CDC
Second FDA-Approved Tocilizumab Biosimilar Has Intravenous, Subcutaneous Formulations
It’s unclear when the new tocilizumab products will be commercially available.
Conference Coverage
Leflunomide: A Fresh Look at an Old Drug
Overlooked in the biologic era, it still has a place.
From the Journals
What Markers Are Helpful to Diagnose Infection in Tocilizumab Users?
The discriminating capacity of certain routinely obtained cell count and protein biomarkers distinguished infected and noninfected adults with...
From the Journals
Autoimmune Disease Risk May Rise Following Cushing Disease Remission After Surgery
The findings suggested the need for closer postsurgical monitoring of patients with a family history of autoimmune disease.
From the Journals
Prognosis of Polyarteritis Nodosa: What Are the Predictors?
Constitutional symptoms were significantly more common in systemic vs. cutaneous disease.
From the Journals
Inflammatory Arthritis Often Occurs with Systemic Sclerosis; Has Big Impact
In patients with systemic sclerosis, the presence of inflammatory arthritis is significantly associated with diffuse disease, musculoskeletal...
Latest News
Mixing Paxlovid With Specific Immunosuppressants Risks Serious Adverse Reactions
The EMA has warned that Paxlovid should only be administered alongside tacrolimus, ciclosporin, everolimus, or sirolimus if their blood levels can...